Details of the Drug Combinations

General Information of This Drug (ID: DMNS70E)

Drug Name

PHA-690509 DMNS70E

Synonyms

PHA-404611; PHA-533533; PNU-252808; PNU-292137; CDK inhibitors (cancer), Nerviano; Cyclin dependent kinase inhibitors (cancer), Nerviano; CDK-2 inhibitors (anticancer), Pfizer; CDK-2 inhibitors (anticancer), Pharmacia

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PHA-690509 + Mitomycin	DC2KIZ1	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
PHA-690509 + PF-562271	DCA5DC5	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
PHA-690509 + Ibrutinib	DCUAESG	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
PHA-690509 + Ruxolitinib	DCCKBMR	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
------------------------------------------------------------------------------------

References

1	Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.